LoVo colon cancer cells resistant to oxaliplatin overexpress c-MET and VEGFR-1 and respond to VEGF with dephosphorylation of c-MET.
about
The c-Met receptor: Implication for targeted therapies in colorectal cancer.Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial.Obstructive Sleep Apnea Monocytes Exhibit High Levels of Vascular Endothelial Growth Factor Secretion, Augmenting Tumor Progression.
P2860
LoVo colon cancer cells resistant to oxaliplatin overexpress c-MET and VEGFR-1 and respond to VEGF with dephosphorylation of c-MET.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
LoVo colon cancer cells resist ...... th dephosphorylation of c-MET.
@en
type
label
LoVo colon cancer cells resist ...... th dephosphorylation of c-MET.
@en
prefLabel
LoVo colon cancer cells resist ...... th dephosphorylation of c-MET.
@en
P2093
P2860
P356
P1476
LoVo colon cancer cells resist ...... ith dephosphorylation of c-MET
@en
P2093
Belén Mezquita
Conchi Mora
Cristóbal Mezquita
Estela Pineda
Joan Maurel
Jordi Codony-Servat
Jovita Mezquita
Montserrat Pau
Pau Mezquita
P2860
P304
P356
10.1002/MC.22289
P577
2015-02-03T00:00:00Z